Branch retinal vein occlusion (BRVO) refers to a heterogeneous group of disorders with different clinical aspects, courses, and probably therapy. Depending on the site of the arteriovenous crossing, we can roughly divide BRVO into 3 main groups: major BRVO, hemispheric retinal vein occlusion, and macular BRVO. Main treatment options include laser treatment, corticosteroid administration, anti-VEGF drugs, and sheathotomy with or without vitrectomy. Laser photocoagulation, as demonstrated by the Branch Vein Occlusion Study, represents the gold standard for the treatment of macular edema and ocular neovascularization following BRVO. The limited functional outcomes achievable by means of laser treatment have prompted researchers to try alternative options, with varying results. The recent introduction of combined therapies for macular edema may provide a superior approach in an attempt to improve and stabilize visual acuity over a long-term follow-up.

1.
Orth D, Patz A: Retinal branch vein occlusion. Surv Ophthalmol 1978;22:357–376.
2.
Klein R, Klein B, Moss SE, Meuer SM: the epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2001;98:133–141.
3.
Feist RM, Ticho BH, Shapiro MJ, Farber M: Branch retinal vein occlusion and quadrantic variation in arteriovenous crossings. Am J Ophthalmol 1992;113:664–668.
4.
Jensen VA: Clinical studies of tributary thrombosis in central retinal vein. Acta Ophthalmol Suppl 1936;10:1–193.
5.
Kumar B, Yu D, Morgan WH, et al: The distribution of angioarchitectural changes within the vicinity of arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998;105:424–427.
6.
Frangieh GT, Green R, Barraquer-Somers E, Finkelstein D: Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982;100:1132–1140.
7.
Baglivo E, Dosso A, Pournaras C: Thrombus and branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1997;235:10–13.
8.
Hayreh SS, Zimmerman MB, Podhajsky P: Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429–441.
9.
Appiah AP, Greenidge KC: Factors associated with retinal vein occlusions in Hispanics. Ann Ophthalmol 1987;19:307–309.
10.
Appiah AP, Trempe CL: Risk factors associated with branch versus central retinal vein occlusion. Ann Ophthalmol 1989;21:153–157.
11.
Appiah AP, Trempe CL: Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions. Ophthalmology 1989;96:364–366.
12.
Coscas G, Dhermy P, Gaudric A; Société Française d’Ophtalmologie: Occlusions veineuses rétiniennes. Paris, Masson, 1978.
13.
Johnston RL, Brucker AJ, Steinmann W, et al: Risk factors of branch retinal vein occlusion. Arch Ophthalmol 1985;103:1831–1832.
14.
Rath EZ, Frank RN, Shin DH, Kim C: Risk factors for retinal vein occlusions. Ophthalmology 1992;99:509–514.
15.
O’Mahoney PRA, Wong DT, Ray JG: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008;126:692–699.
16.
The Eye Disease Case-Control Study Group: Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286–296.
17.
Frucht J, Shapiro A, Merin S: Intraocular pressure in retinal vein occlusion. Br J Ophthalmol 1984;68:26–28.
18.
Cole MD, Dodson PM, Hendeles S: Medical conditions underlying retinal vein occlusion in patients with glaucoma or ocular hypertension. Br J Ophthalmol 1989;73:693–698.
19.
McGrath MA, Wechsler F, Hunyor ABL, Penny R: Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978;138:216–220.
20.
Dodson PM, Galton DJ, Hamilton AM, Black RK: Retinal vein occlusion and the prevalence of lipoprotein abnormalities. Br J Ophthalmol 1982;66:161–164.
21.
Trope GE, Lowe GDO, McArdle BM: Abnormal blood viscosity and hemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983;67:137–142.
22.
Remky A, Arend O, Jung F, et al: Haemorheology in patients with branch retinal vein occlusion with and without risk factors. Graefes Arch Clin Exp Ophthalmol 1996;234 (suppl 1):S8–S12.
23.
Glacet-Bernard A, Bayani N, Chretien P, et al: Antiphospholipid antibodies in retinal vein occlusion: a prospective study of 75 patients. Arch Ophthalmol 1994;112:790–795.
24.
Majji AB, Janarthanan M, Naduvilath TJ: Significance of refractive status in branch retinal vein occlusion: a case-control study. Retina 1997;17:200–204.
25.
Timmerman EA, de Lavalette VW, van den Brom HJB: Axial length as risk factor to branch retinal vein occlusion. Retina 1989;17:196–199.
26.
Bandello F, Tavola A, Pierro L, et al: Axial length and refraction in retinal vein occlusions. Ophthalmologica 1998;212:133–135.
27.
Cursiefen C, Handel A, Schonherr U, Naumann GO: Pseudoexfoliation syndrome in patients with retinal vein branch and central vein thrombosis. Klin Monatsbl Augenheilkd 1997;211:17–21.
28.
Henkind P, Wise GN: Retinal neovascularization, collaterals, and vascular shunts. Br J Ophthalmol 1974;58:413–422.
29.
Pieris SJ, Hill DW: Collaterals vessels in branch retinal vein occlusion. Trans Ophthalmol Soc UK 1982;102:178–181.
30.
Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF: Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488–506.
31.
Silva RM, Faria de Abreu JR, Cunha-Vaz JG: Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol 1995;233:721–726.
32.
Michels RG, Gass JDM: The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 1974;78:166–177.
33.
Gutman FA, Zegarra H: The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974;78:178–192.
34.
Blankenship GW, Okun E: Retinal tributary vein occlusion: history and management by photocoagulation. Arch Ophthalmol 1973;89:363–368.
35.
Trempe CL, Takahashi M, Topilow HW: Vitreous changes in retinal branch vein occlusion. Ophthalmology 1981;88:681–687.
36.
Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986;104:34–41.
37.
Hayreh SS, Rubenstein L, Podhajsky P: Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion: a prospective clinical trial. Ophthalmologica 1993;206:1–14.
38.
Apostolopoulos M, Koutsandrea C, Chatjoulis D, et al: Late complications in branch retinal vein occlusion. Int Ophthalmol 1996;19:281–285.
39.
Takahashi MK, Hikichi T, Akiba J, Yoshida A, Trempe CL: Role of the vitreous and macular edema in branch retinal vein occlusion. Ophthalmic Surg Lasers 1997;28:294–299.
40.
Kado M, Trempe CL: Role of the vitreous in branch retinal vein occlusion. Am J Ophthalmol 1988;105:20–24.
41.
Schepens CL, Avila MP, Jalkh AE, Trempe CL: Role of the vitreous in cystoid macular edema. Surv Ophthalmol 1984;28:499–504.
42.
Finkelstein D, Clarkson J, Diddie K, Hillis A, Kimball A, Orth D, Trempe C; The Branch Vein Occlusion Study Group: Branch vein occlusion: retinal neovascularization outside the involved segment. Ophthalmology 1982;89:1357–1361.
43.
Greer DV, Constable IJ, Cooper RL: Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 1980;8:207–209.
44.
Gass JDM: Stereoscopic atlas of macular diseases. St. Louis, Mosby, 1970, p 154.
45.
Chess J, Eichen AL: Rhegmatogenous retinal detachment associated with branch vein occlusion. Ann Ophthalmol 1989;21:309–311.
46.
Ikuno Y, Tano Y, Lewis JR, Ikeda T, Sato Y: Retinal detachment after branch retinal vein occlusion: influence of the type of break on the outcome of vitreous surgery. Ophthalmology 1997;104:27–32.
47.
Ikuno Y, Ikeda T, Sato Y, Tano Y: Tractional retinal detachment after branch retinal vein occlusion: influence of disc neovascularization on the outcome of vitreous surgery. Ophthalmology 1998;105:417–423.
48.
Metzler U, Hollmann R, Kaskel D: Netzhautablösungen bei Verschlüssen der Zentralvene oder ihrer Äste. Klin Monatsbl Augenheilkd 1974;164:251–254.
49.
Schatz H, Yannuzzi L, Stransky TJ: Retinal detachment secondary to branch vein occlusion. Part I. Ann Ophthalmol 1976;8:1437–1452.
50.
Schatz H, Yannuzzi L, Stransky TJ: Retinal detachment secondary to branch vein occlusion. Part II. Ann Ophthalmol 1976;8:1461–1471.
51.
Ravalico G, Battaglia Parodi M: Exudative retinal detachment subsequent to retinal vein occlusion. Ophthalmologica 1992;205:77–82.
52.
Battaglia Parodi M, Isola V: Branch retinal vein occlusion and exudative retinal detachment: pathogenetical aspects. Ophthalmologica 1994;208:29–31.
53.
Battaglia Parodi M, Ravalico G: Letter. Retina 1995;15:73–74.
54.
Cousins SW, Flynn HW, Clarkson JG: Macroaneurysms associated with retinal branch vein occlusion. Am J Ophthalmol 1990;109:567–570.
55.
Battaglia Parodi M, Da Pozzo S, Saviano S, Ravalico G: Branch retinal vein occlusion and macroaneurysms. Int Ophthalmol 1997;21:161–164.
56.
Hayreh SS, Hayreh MS: Hemi-central retinal vein occlusion: pathogenesis, clinical features and natural history. Arch Ophthalmol 1980;98:1600–1609.
57.
Hayreh SS: Letter. Ophthalmologica 1987;194:154–156.
58.
Chopdar A: Hemispheric retinal vein occlusion or hemicentral retinal vein occlusion. Arch Ophthalmol 1986;104:1128.
59.
Battaglia Parodi M, Moretti G, Ravalico G: Hemicentral and hemispheric retinal vein occlusions. Metab Pediatr Syst Ophthalmol 1992;15:64–67.
60.
Sperduto RD, Hiller R, Chew E, et al: Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion. The eye disease case-control study. Ophthalmology 1998;105:765–771.
61.
Joffe L, Goldsberg RE, Magargal LE, Annesley WH: Macular branch vein occlusion. Ophthalmology 1980;87:91–98.
62.
Notting JGA, Van Der Werf PJP: Macular changes caused by occlusion of a minute venous branch. Ophthalmologica 1976;173:200–206.
63.
Battaglia Parodi M, Della Rupe P, Visintin F, Ravalico G: Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol 1995;19:25–28.
64.
Battaglia Parodi M, Saviano S, Ravalico G: Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999;237:1024–1027.
65.
Virgili G, Caucci S, Lanzetta P, et al: Retinal neovascularization in a case of macular branch retinal vein occlusion. Greafes Arch Clin Exp Ophthalmol 1997;235:603–605.
66.
Houtsmuller AJ, Vermeulen JA, Klompe M, et al: The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984;15:219–229.
67.
Glacet-Bernard A, Coscas G, Chabanel A, et al: A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421–429.
68.
Kiryu J, Ogura Y: Hyperbaric oxygen treatment for macular edema in retinal vein occlusion: relation to severity of retinal leakage. Ophthalmologica 1996;210:168–170.
69.
Chen HC, Wiek J, Gupta A, et al: Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998;82:162–167.
70.
Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271–282.
71.
Shilling JS, Jones CA: Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular edema. Br J Ophthalmol 1984;68:196–198.
72.
Roseman RL, Olk RJ: Krypton red laser photocoagulation for branch retinal vein occlusion. Ophthalmology 1987;94:1120–1125.
73.
Finkelstein D: Ischemic macular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992;110:1427–1434.
74.
Battaglia Parodi M, Spasse S, Iacono P, et al: Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006;113:2237–2242.
75.
Opremcak EM, Bruce RA: Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999;19:1–5.
76.
Shah GH, Sharma S, Fineman MS, et al: Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2000;129:104–106.
77.
Le Ruic JF, Bejjani RA, Rumen F, et al: Adventitial sheathotomy for decompression of recent onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2001;239:747–751.
78.
Cahill MT, Kaiser PK, Sears JE, Fekrat S: The effect of arteriovemous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2003;87:1329–1332.
79.
Mason J 3rd, Feist R, White M, et al: Sheathotomy to decompress branch retinal vein occlusion. Ophthalmology 2004;111:540–545.
80.
Yamamoto S, Saito W, Yagi F, et al: Vitrectomy with and without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004;138:907–914.
81.
Kumagai K, Furukawa M, Ogino N, et al: Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina 2007;27:49–54.
82.
Charbonnel J, Glacet-Bernard A, Korobelnik J, et al: Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy: the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 2004;242:223–228.
83.
Tachi N, Hashimoto Y, Ogino N: Vitrectomy for macular oedema combined with retinal vein occlusion. Doc Ophthalmol 1999;97:465–469.
84.
Amirikia A, Scott IU, Murray TG, et al: Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion. Ophthalmology 2001;108:372–376.
85.
Saika S, Tanaka T, Miyamoto T, Ohnishi Y: Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular oedema associated with branch retinal vein occlusion: retinal tomography and visual outcome. Graefes Arch Clin Exp Ophthalmol 2001;239:729–732.
86.
Stefansson E, Novack RL, Hatchell DL: Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci 1990;31:284–289.
87.
Shimura M, Nakazawa T, Yasuda K, et al: Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema. Acta Ophthalmol 2008;86:377–384.
88.
Dagenring RF, Kamppeter B, Kreissig I, et al: Morphological and functional changes after intravitreal triamcinolone for retinal vein occlusion. Acta Ophthalmol Scand 2003;81:548–550.
89.
Chen SDM, Lochhead J, Patel CK, et al: Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 2004;88:154–155.
90.
Jonas JB, Akkyyun I, Kamppeter B, et al: Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65–71.
91.
Patel PJ, Zaheer I, Karia N: Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 2008;22:60–64.
92.
Cekic O, Chang S, Tseng JJ, et al: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851–855.
93.
Hayashi K, Hayashi H: Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005;139:972–982.
94.
Kawaji T, Takano A, Inomata Y, et al: Trans-Tanon’s retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion. Br J Ophthalmol 2008;92:81–83.
95.
Kuppermann BD, Blumenkranz MS, Haller JA, et al: Randomized controlled study of an intravitreous dexamathasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–317.
96.
Noma H, Funatsu H, Yamasaki M, et al: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256–261.
97.
Noma H, Minamoto A, Funatsu H, et al: Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309–315.
98.
Pai SA, Shetty R, Vijiayan PB, et al: Clinic, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601–606.
99.
Rabena MD, Pieramici DJ, Castellarin AA, et al: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419–425.
100.
Kreutzer TC, Alge CS, Wolf AH, et al: Intravitreal bevacizumab for the treatment of macula oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351–355.
101.
Wu L, Arevalo JF, Roca JA, et al: Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212–219.
102.
Funk M, Kriechbaum KF, Prager F, et al: Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025–1032.
103.
Jaissle GB, Leitritz M, Gelisken F, et al: One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27–33.
104.
Prager F, Michels S, Kriechbaum K, et al: Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: twelve-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452–456. DOI: 10.1136/bjo.2008. 141085.
105.
Chung EJ, Hong YT, Lee SC, et al: Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241–1247.
106.
Campochiaro PA, Hafiz G, Shah SM, et al: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791–799.
107.
Riese J, Loukopoulos V, Meier C, et al: Combined intravitreal triamcinlone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671–1676.
108.
Cakir M, Dogan M, Bayraktar Z, et al: Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with and without grid laser photocoagulation. Retina 2008;28:465–472.
109.
Parodi MB, Iacono P, Ravalico G: Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 2008;92:1046–1050.
110.
Jin M, Ke Y, Zheng Z, Xiajing T: Twenty-five-gauge vitrectomy and triamcinolone acetonide-assisted internal limiting membrane peeling for chronic macular edema associated with branch retinal vein occlusion. Retina 2008;28:947–956.
111.
Uemura A, Yamamoto S, Sato E, et al: Vitrectomy alone versus vitrectomy with simultaneous injection of triamcinolone for macular edema associated with branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2009;40:6–12.
112.
Garcia-Arumi J, Martinez-Castillo V, Boixadera A, et al: Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina 2004;24:530–540.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.